Showing 56 news articles about Injectable & long-acting PrEP

Filters Content type: Editors' picks Topic: Injectable & long-acting PrEP

The antiretroviral drug cabotegavir, administered every eight weeks as an injection, has been shown to be safe and effective in preventing HIV infection in men who have sex with men. Studies in women are ongoing and scientists are also working on a long-acting PrEP implant.

Uganda moves forward on PrEP vaginal ring and injection

Editor's pick
Be In The Know
20 December 2022

CAB-LA's Full Potential for HIV Prevention Hits Snags

Editor's pick
Medscape (requires free registration)
13 December 2022